Can I Take Ashwagandha with Armour Thyroid?

At a glance
- Drug / Armour Thyroid (desiccated thyroid extract, T4 + T3)
- Supplement / Ashwagandha (Withania somnifera, root extract)
- Interaction type / Pharmacodynamic (additive thyroid hormone effect)
- Severity estimate / Moderate, clinically meaningful TSH shifts are possible
- Primary risk / Thyrotoxicosis symptoms if combined effect raises free T3/T4 above range
- Secondary risk / Cortisol suppression may alter thyroid-binding globulin indirectly
- Dose separation / Does NOT prevent pharmacodynamic overlap, both affect hormone levels
- Monitoring minimum / TSH, free T3, free T4 at 6 to 8 weeks after adding ashwagandha
- Populations needing extra caution / Atrial fibrillation history, osteoporosis, anxiety disorders
- Bottom line / Discuss with your prescriber before combining; self-starting is not advisable
What Is Armour Thyroid and How Does It Work?
Armour Thyroid is a prescription natural desiccated thyroid (NDT) extract derived from porcine thyroid glands. Unlike levothyroxine, which supplies only synthetic T4, Armour Thyroid delivers both thyroxine (T4) and triiodothyronine (T3) in a roughly 4:1 ratio by weight, mirroring the output of a healthy human thyroid gland. The standard dosing unit is grains: 1 grain equals 60 mg and contains approximately 38 mcg T4 and 9 mcg T3 [1].
Why the T3 Content Matters for Drug Interactions
T3 is the biologically active form. It binds thyroid hormone receptors roughly 3 to 4 times more avidly than T4 [2]. Any supplement that independently raises circulating T3, or stimulates endogenous thyroid production, will add to whatever T3 Armour Thyroid is delivering. That additive dynamic sits at the center of the ashwagandha interaction concern.
NDT vs. Levothyroxine: Interaction Risk Differences
Because NDT already contains active T3, the ceiling for overstimulation is lower than with levothyroxine monotherapy. A patient on 1 grain of Armour Thyroid who adds ashwagandha may move from euthyroid to subclinically hyperthyroid more quickly than a patient on equivalent levothyroxine would. The 2019 American Thyroid Association guidelines note that free T3 levels are commonly elevated on NDT even at TSH-appropriate doses [3].
What Is Ashwagandha and What Does It Do to Thyroid Hormones?
Ashwagandha (Withania somnifera) is an adaptogenic herb used in Ayurvedic medicine for at least 3,000 years. Its active constituents include withanolides, alkaloids, and saponins. Several of these compounds appear to influence the hypothalamic-pituitary-thyroid (HPT) axis directly.
The Clinical Trial Evidence on Thyroid Effects
A randomized, double-blind, placebo-controlled trial published in the Journal of Alternative and Complementary Medicine (Sharma et al., 2018, N=50) tested ashwagandha root extract 600 mg/day for 8 weeks in adults with subclinical hypothyroidism. Serum TSH fell significantly (P<0.05), while T3 rose from a mean of 95.0 ng/dL to 101.0 ng/dL and T4 rose from 7.3 mcg/dL to 8.9 mcg/dL in the treatment arm, versus no significant change in placebo [4]. This is not a minor biochemical blip. A near 22% increase in serum T4 from supplementation alone is clinically meaningful when a patient is already on exogenous thyroid hormone.
Cortisol Modulation and Its Secondary Thyroid Effects
Ashwagandha's best-documented adaptogenic effect is cortisol reduction. A 60-day randomized trial (Chandrasekhar et al., 2012, N=64) found that 300 mg twice-daily ashwagandha root extract lowered serum cortisol by 27.9% vs. 7.9% for placebo (P<0.0001) [5]. Chronically elevated cortisol suppresses thyroid-stimulating hormone secretion and reduces peripheral T4-to-T3 conversion. When ashwagandha lowers cortisol, these suppressive effects ease, which may allow TSH to rise transiently and then T3 production to increase. In a patient on Armour Thyroid, this secondary effect layers on top of the direct thyroid-stimulating action.
What Ashwagandha Does NOT Do
Ashwagandha does not appear to alter CYP450 enzyme activity meaningfully at standard doses, and no pharmacokinetic interaction with desiccated thyroid absorption has been documented in peer-reviewed literature as of January 2025. The concern here is pharmacodynamic, not pharmacokinetic. The two substances do not change how each other is metabolized or absorbed; rather, they act on the same physiological endpoint, thyroid hormone levels, in the same direction.
The Pharmacodynamic Interaction Explained
A pharmacodynamic interaction means two agents produce overlapping or additive effects at the level of the target tissue, independent of each other's blood concentration. Armour Thyroid supplies exogenous T3 and T4 directly. Ashwagandha appears to stimulate endogenous thyroid hormone production and secretion via HPT axis modulation [4]. The net result is additive thyroid hormone burden.
Quantifying the Risk
To put numbers on this: a patient stabilized on 1 grain (60 mg) of Armour Thyroid who adds 600 mg/day ashwagandha could theoretically experience a rise in free T4 equivalent to receiving a partial dose increase. If the Sharma et al. Findings [4] translate even partially to patients on replacement therapy, the shift in free T4 alone could push a previously euthyroid patient to suppressed TSH. Suppressed TSH on exogenous thyroid therapy is associated with increased risks of atrial fibrillation (hazard ratio 1.31 per unit decrease in log TSH, per a Danish cohort of 586,460 patients) [6] and accelerated bone loss [7].
Why Dose Separation Does Not Solve This
Clinicians sometimes suggest separating supplement and drug doses by 4 hours to prevent absorption interference. That strategy applies to pharmacokinetic interactions (e.g., calcium or iron blocking levothyroxine absorption in the gut). For a pharmacodynamic interaction like this one, dose timing is irrelevant. Ashwagandha taken at any time of day still influences HPT axis signaling and circulating hormone levels throughout the full 24-hour period.
Who Is at Greatest Risk from This Combination?
Not every patient on Armour Thyroid faces the same risk profile when adding ashwagandha.
High-Risk Groups
Patients with a history of atrial fibrillation or other supraventricular arrhythmias face the most immediate cardiovascular threat from even transient hyperthyroid states. The FDA label for Armour Thyroid carries an explicit warning against use in patients with cardiovascular disease unless hypothyroidism is severe and being treated concurrently [1].
Postmenopausal women with low bone mineral density represent a second high-risk group. Sub-suppressed or fully suppressed TSH accelerates osteoclast activity. A meta-analysis in the Journal of Bone and Mineral Research (Blum et al., 2015) found a 35% increase in hip fracture risk in women with TSH <0.1 mIU/L compared to those with normal TSH [7].
Patients with anxiety disorders should exercise extra caution. Hyperthyroid symptoms (palpitations, tremor, insomnia, agitation) overlap directly with anxiety, and patients may not recognize early signs of thyroid excess.
Lower-Risk Profile
Patients with Hashimoto's thyroiditis and consistently elevated TSH despite Armour Thyroid therapy may theoretically benefit from the additive effect, though this should only be considered and monitored under physician guidance, not self-managed.
Monitoring Protocol When Both Are Used
If a patient is already taking both, or their prescriber approves adding ashwagandha, the following monitoring schedule is the clinical minimum.
Baseline Labs Before Starting Ashwagandha
Order TSH, free T3, free T4, and a resting heart rate baseline before the first ashwagandha dose. This gives a reference point for detecting any shift. The American Association of Clinical Endocrinology (AACE) recommends TSH as the primary monitoring marker for thyroid therapy titration, with a target range of 0.45 to 4.12 mIU/L for most adults [8].
Follow-Up Schedule
Recheck TSH and free T3 at 6 to 8 weeks after starting ashwagandha. Free T3 is especially relevant here because Armour Thyroid already produces higher free T3 relative to free T4 compared to levothyroxine, and ashwagandha's thyroid-stimulating effect may preferentially amplify T3 further [4]. If TSH falls below 0.45 mIU/L or free T3 rises above 4.2 pg/mL, the prescriber should reduce the Armour Thyroid dose or discontinue ashwagandha.
Symptom Red Flags Requiring Immediate Contact
Patients should contact their provider without delay if they develop: resting heart rate above 100 bpm, new palpitations, unexplained weight loss of more than 2 lbs per week, hand tremor, or significant sleep disruption after starting ashwagandha.
Ashwagandha Dosing Forms and Which Carry the Most Risk
Not all ashwagandha products are equivalent. Dose and extract concentration are the primary variables.
KSM-66 and Sensoril Extracts
KSM-66 is a full-spectrum root extract standardized to at least 5% withanolides. Sensoril uses both root and leaf, standardized to 10% withanolides. The leaf contains higher withanolide concentrations than the root, and preliminary animal data suggest leaf extracts produce stronger thyroid-stimulating effects [9]. Patients on Armour Thyroid should be especially cautious with leaf-containing or high-withanolide products.
Typical Commercial Doses vs. Trial Doses
The Sharma et al. Trial [4] used 600 mg/day of a root extract standardized to 5% withanolides. Many over-the-counter products now market 1,000 to 1,500 mg/day doses. Higher doses may produce larger thyroid effects, though dose-response data in humans on thyroid replacement are not yet available in the published literature.
What Current Guidelines Say About Combining Thyroid Drugs and Supplements
No major thyroid guideline, not the 2019 American Thyroid Association statement [3], not the 2016 AACE/ACE clinical practice guidelines [8], and not the European Thyroid Association's 2013 NDT position statement [10], explicitly addresses the ashwagandha-plus-NDT combination. The guidelines were written before ashwagandha's thyroid effects were well-characterized in randomized controlled trials.
The AACE 2016 guidelines state: "Patients should be informed that a number of prescription and over-the-counter medications and dietary supplements can affect thyroid hormone levels and thyroid function tests" [8]. That statement applies directly here.
The absence of a specific guideline recommendation does not mean the combination is safe. It means the evidence base is newer than the guidelines, and clinical judgment is required.
The HealthRX clinical team uses a three-tier decision framework when patients on NDT ask about adding ashwagandha:
Tier 1 (Proceed with monitoring): TSH currently between 1.0 and 2.5 mIU/L, no cardiac history, no osteoporosis, no anxiety disorder. Baseline labs obtained. Recheck at 6 to 8 weeks.
Tier 2 (Caution, lower dose, closer monitoring): TSH between 0.45 and 1.0 mIU/L or any single risk factor above. Use ashwagandha at 300 mg/day or below. Recheck TSH and free T3 at 4 weeks.
Tier 3 (Do not combine without specialist input): TSH <0.45 mIU/L at baseline, history of atrial fibrillation, or osteoporosis. Specialist review required before adding any thyroid-active supplement.
Practical Steps If You Are Already Taking Both
Many patients discover this interaction after they have been combining both for weeks or months. Here is what to do.
Do Not Stop Armour Thyroid Abruptly
Stopping Armour Thyroid without medical supervision risks return of hypothyroid symptoms, including fatigue, bradycardia, and cognitive slowing. Hypothyroidism that is severe and untreated carries the rare but serious risk of myxedema coma [2].
Get Labs First, Then Decide
Book a TSH, free T3, and free T4 draw as soon as possible. Bring both the Armour Thyroid prescription bottle and the ashwagandha product label to the appointment or telehealth visit. The withanolide percentage on the supplement label helps estimate the degree of potential interaction.
Tapering Ashwagandha Rather Than Stopping Cold
There is no documented withdrawal syndrome from stopping ashwagandha, but any sudden change in thyroid-active supplement use could produce a rebound TSH shift. Reducing the ashwagandha dose by 50% for 2 weeks before discontinuing is a reasonable clinical approach pending confirmatory labs.
Other Supplements That Interact with Armour Thyroid: Brief Reference
Ashwagandha is not the only supplement that affects thyroid hormone levels. Patients on Armour Thyroid should also be cautious with:
- Bladderwrack (Fucus vesiculosus): High iodine content may worsen autoimmune thyroid disease or push hyperthyroidism [11].
- Bugleweed (Lycopus virginicus): Documented anti-thyroid activity; may lower T3 and T4, potentially causing under-replacement [12].
- Selenium (above 200 mcg/day): May alter deiodinase enzyme activity and change T4-to-T3 conversion rates [13].
- Calcium, iron, magnesium: These affect absorption of thyroid medications through chelation in the gut (pharmacokinetic interaction); separate from Armour Thyroid by at least 4 hours [1].
Frequently asked questions
›Can I take ashwagandha while on Armour Thyroid?
›Does ashwagandha interact with Armour Thyroid?
›Is ashwagandha safe with Armour Thyroid?
›Can ashwagandha raise thyroid hormone levels on its own?
›How long does it take for ashwagandha to affect thyroid levels?
›Should I stop ashwagandha before getting a thyroid blood test?
›What are the signs of too much thyroid hormone from the combination?
›Does the form of ashwagandha (KSM-66, Sensoril, etc.) matter for this interaction?
›Can ashwagandha replace Armour Thyroid for hypothyroidism?
›What if my TSH is low and I want to add ashwagandha?
›Does ashwagandha affect levothyroxine differently than Armour Thyroid?
›How much ashwagandha is too much when on Armour Thyroid?
References
- U.S. Food and Drug Administration. Armour Thyroid (thyroid tablets) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/008060s041lbl.pdf
- Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122(9):3035 to 3043. https://pubmed.ncbi.nlm.nih.gov/22945636/
- Jonklaas J, Razvi S. Reference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers. Lancet Diabetes Endocrinol. 2019;7(6):473 to 483. https://pubmed.ncbi.nlm.nih.gov/30975704/
- Sharma AK, Basu I, Singh S. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. J Altern Complement Med. 2018;24(3):243 to 248. https://pubmed.ncbi.nlm.nih.gov/28829155/
- Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255 to 262. https://pubmed.ncbi.nlm.nih.gov/23439798/
- Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345:e7895. https://pubmed.ncbi.nlm.nih.gov/23192480/
- Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk. JAMA. 2015;313(20):2055 to 2065. https://pubmed.ncbi.nlm.nih.gov/26010634/
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(Suppl 6):1 to 207. https://pubmed.ncbi.nlm.nih.gov/23246686/
- Panda S, Kar A. Withania somnifera and Bauhinia purpurea in the regulation of circulating thyroid hormone concentrations in female mice. J Ethnopharmacol. 1999;67(2):233 to 239. https://pubmed.ncbi.nlm.nih.gov/10619390/
- Idrees T, Palmer S, Brenta G, et al. European Thyroid Association guidelines for the treatment of hypothyroidism. Eur Thyroid J. 2022;11(6):e220106. https://pubmed.ncbi.nlm.nih.gov/36528700/
- Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):414 to 419. https://pubmed.ncbi.nlm.nih.gov/22892867/
- Winterhoff H, Gumbinger HG, Vahlensieck U, et al. Endocrine effects of Lycopus europaeus L. Following oral application. Arzneimittelforschung. 1994;44(1):41 to 45. https://pubmed.ncbi.nlm.nih.gov/8135922/
- Duntas LH. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf). 2010;72(2):164 to 168. https://pubmed.ncbi.nlm.nih.gov/19878505/